Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Celcuity Inc's Business Segments
Celcuity Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
1
Largest Segment
Product
Total Revenue
-
Regions Reported
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CELC/segments
https://api.csimarket.com/api/v1/companies/CELC/geographic
https://api.csimarket.com/api/v1/companies/CELC/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Revenue Share by Reportable Segment -
- Product0%
Revenue by Reportable Segment -
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | - | - |
Annual Results
Revenue Share by Reportable Segment -
- Product0%
Revenue by Reportable Segment -
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | - | - |
Description of Celcuity Inc
Celcuity Inc. is a healthcare technology company that specializes in developing and commercializing cell-based diagnostic tests. The company is focused on utilizing a patient's own living cells to identify which targeted therapies are most likely to be effective for their specific type of cancer.
Celcuity's innovative approach involves analyzing the signaling activity in a patient's cancer cells to determine the presence of abnormal cellular pathways. By measuring the level of activated signaling proteins within the tumor cells, they can determine if the cancer is being driven by specific altered signaling pathways. This information can then be used to guide treatment decisions, as certain targeted therapies are designed to inhibit these specific pathways and halt the growth and progression of the cancer.
One of Celcuity's primary products is its CELx HSF test, which stands for High Sensitivity Functional Test. This test is designed to detect functional abnormalities in the signaling pathways of a patient's tumor cells, potentially uncovering alterations that are missed by traditional genomic tests. By identifying these abnormalities, the CELx HSF test can help guide treatment decisions and improve patient outcomes.
Celcuity's technology is based on an extensive body of scientific research conducted by its team of experts and collaborators. They leverage their knowledge of cellular signaling pathways and their dysregulation in cancer to develop tests that have the potential to optimize treatment selection for patients. Their approach is focused on providing physicians with actionable information that can lead to more targeted and personalized therapies.
In addition to the CELx HSF test, Celcuity is actively working on expanding its product portfolio. They have ongoing clinical trials to evaluate the effectiveness of their tests in various cancer types, such as breast cancer, lung cancer, and ovarian cancer. The company is also exploring partnerships and collaborations with pharmaceutical companies to develop companion diagnostics that can be used alongside targeted therapies to identify patients who are most likely to benefit from a specific treatment.
Overall, Celcuity Inc. is at the forefront of precision medicine in oncology. Their cell-based diagnostic tests have the potential to significantly improve treatment decision-making by providing physicians with valuable insights into the underlying signaling pathways driving a patient's cancer. By leveraging the power of cellular analysis, Celcuity aims to transform the way cancer is diagnosed and treated, ultimately leading to better outcomes for patients.
Celcuity's innovative approach involves analyzing the signaling activity in a patient's cancer cells to determine the presence of abnormal cellular pathways. By measuring the level of activated signaling proteins within the tumor cells, they can determine if the cancer is being driven by specific altered signaling pathways. This information can then be used to guide treatment decisions, as certain targeted therapies are designed to inhibit these specific pathways and halt the growth and progression of the cancer.
One of Celcuity's primary products is its CELx HSF test, which stands for High Sensitivity Functional Test. This test is designed to detect functional abnormalities in the signaling pathways of a patient's tumor cells, potentially uncovering alterations that are missed by traditional genomic tests. By identifying these abnormalities, the CELx HSF test can help guide treatment decisions and improve patient outcomes.
Celcuity's technology is based on an extensive body of scientific research conducted by its team of experts and collaborators. They leverage their knowledge of cellular signaling pathways and their dysregulation in cancer to develop tests that have the potential to optimize treatment selection for patients. Their approach is focused on providing physicians with actionable information that can lead to more targeted and personalized therapies.
In addition to the CELx HSF test, Celcuity is actively working on expanding its product portfolio. They have ongoing clinical trials to evaluate the effectiveness of their tests in various cancer types, such as breast cancer, lung cancer, and ovarian cancer. The company is also exploring partnerships and collaborations with pharmaceutical companies to develop companion diagnostics that can be used alongside targeted therapies to identify patients who are most likely to benefit from a specific treatment.
Overall, Celcuity Inc. is at the forefront of precision medicine in oncology. Their cell-based diagnostic tests have the potential to significantly improve treatment decision-making by providing physicians with valuable insights into the underlying signaling pathways driving a patient's cancer. By leveraging the power of cellular analysis, Celcuity aims to transform the way cancer is diagnosed and treated, ultimately leading to better outcomes for patients.
Celcuity Inc. is a biotechnology company focused on advancing precision medicine, primarily for cancer treatment. The company has developed a proprietary platform that aims to enhance the identification and treatment of cancer by enabling a deeper understanding of a patients tumor biology. Here’s an extensive overview of the segments, products, and services that Celcuity offers:
Segments
1. Precision Medicine: Celcuity operates within the precision medicine sector, aiming to tailor treatments based on the individual genetic makeup and molecular characteristics of a patients cancer.
2. Biotechnology R&D: The company is engaged in research and development (R&D) activities that focus on the discovery and development of novel cancer therapeutics.
3. Clinical Development: Celcuity is involved in the clinical development of its product candidates, leading to potential partnerships with pharmaceutical companies for FDA approval and commercialization.
4. Diagnostic Services: This includes the capabilities to identify specific biomarkers in tumors that can inform treatment decisions, thus enhancing the personalized treatment approach.
Products
Celcuity has a primarily focused pipeline that includes the following prominent products:
1. CELsignia™ Platform:
- This is an innovative cell-based diagnostic platform designed to identify how tumor cells respond to various cancer therapies. By mimicking the tumor environment, this platform assesses the therapeutic effectiveness of existing and investigational drugs at the cellular level.
- The CELsignia testing process includes the analysis of live tumor cells from a patient, allowing for real-time insights into the tumors characteristics.
- The results from CELsignia can help oncologists in making informed decisions regarding the most effective treatment options for patients, ultimately leading to improved patient outcomes.
2. Investigational Therapeutics:
- Celcuity is developing several investigational drugs targeting specific oncogenic pathways. These drugs are designed to address unmet medical needs in cancer treatment and are currently undergoing various stages of clinical trials.
- Specific product candidates may target driving mutations in cancer and leverage novel mechanisms of action, enhancing their therapeutic potential.
Services
1. Biomarker Discovery: Celcuity provides services in biomarker discovery, focusing on identifying new biomarkers that can help classify and stratify cancer patient populations. This can lead to the development of targeted treatments and improved diagnostics.
2. Clinical Trial Services: Celcuity collaborates with other entities to streamline clinical trial processes. This includes patient recruitment, monitoring efficacy, and collecting data for validation of therapeutic interventions.
3. Consultation for Oncologists: Celcuity may offer consultation services that aid oncologists in understanding the results from their diagnostic platforms and how these results can influence treatment plans. This personalized approach aims to enhance patient care by integrating cutting-edge research findings into clinical practice.
4. Partnership Development: The company actively seeks partnerships with pharmaceutical and biotechnology companies to co-develop therapeutics and expand the access and application of its CELsignia platform in various oncology settings.
Conclusion
Through its commitment to precision medicine, Celcuity Inc. aims to transform cancer treatment by providing tools and products that facilitate personalized therapies based on the distinct molecular profiles of tumors. By focusing on innovative diagnostic technologies like the CELsignia platform and developing next-generation therapeutics, the company is positioned to make significant contributions to the field of oncology and improve patient outcomes. Through its comprehensive suite of services, it strives to enhance the effectiveness of cancer treatments and ensure that patients receive the most appropriate care based on their unique cancer profiles.
Segments
1. Precision Medicine: Celcuity operates within the precision medicine sector, aiming to tailor treatments based on the individual genetic makeup and molecular characteristics of a patients cancer.
2. Biotechnology R&D: The company is engaged in research and development (R&D) activities that focus on the discovery and development of novel cancer therapeutics.
3. Clinical Development: Celcuity is involved in the clinical development of its product candidates, leading to potential partnerships with pharmaceutical companies for FDA approval and commercialization.
4. Diagnostic Services: This includes the capabilities to identify specific biomarkers in tumors that can inform treatment decisions, thus enhancing the personalized treatment approach.
Products
Celcuity has a primarily focused pipeline that includes the following prominent products:
1. CELsignia™ Platform:
- This is an innovative cell-based diagnostic platform designed to identify how tumor cells respond to various cancer therapies. By mimicking the tumor environment, this platform assesses the therapeutic effectiveness of existing and investigational drugs at the cellular level.
- The CELsignia testing process includes the analysis of live tumor cells from a patient, allowing for real-time insights into the tumors characteristics.
- The results from CELsignia can help oncologists in making informed decisions regarding the most effective treatment options for patients, ultimately leading to improved patient outcomes.
2. Investigational Therapeutics:
- Celcuity is developing several investigational drugs targeting specific oncogenic pathways. These drugs are designed to address unmet medical needs in cancer treatment and are currently undergoing various stages of clinical trials.
- Specific product candidates may target driving mutations in cancer and leverage novel mechanisms of action, enhancing their therapeutic potential.
Services
1. Biomarker Discovery: Celcuity provides services in biomarker discovery, focusing on identifying new biomarkers that can help classify and stratify cancer patient populations. This can lead to the development of targeted treatments and improved diagnostics.
2. Clinical Trial Services: Celcuity collaborates with other entities to streamline clinical trial processes. This includes patient recruitment, monitoring efficacy, and collecting data for validation of therapeutic interventions.
3. Consultation for Oncologists: Celcuity may offer consultation services that aid oncologists in understanding the results from their diagnostic platforms and how these results can influence treatment plans. This personalized approach aims to enhance patient care by integrating cutting-edge research findings into clinical practice.
4. Partnership Development: The company actively seeks partnerships with pharmaceutical and biotechnology companies to co-develop therapeutics and expand the access and application of its CELsignia platform in various oncology settings.
Conclusion
Through its commitment to precision medicine, Celcuity Inc. aims to transform cancer treatment by providing tools and products that facilitate personalized therapies based on the distinct molecular profiles of tumors. By focusing on innovative diagnostic technologies like the CELsignia platform and developing next-generation therapeutics, the company is positioned to make significant contributions to the field of oncology and improve patient outcomes. Through its comprehensive suite of services, it strives to enhance the effectiveness of cancer treatments and ensure that patients receive the most appropriate care based on their unique cancer profiles.